Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Intermittent Claudication Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The intermittent claudication market has seen significant growth in recent years. It is anticipated to expand from $13.51 billion in 2025 to $14.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. The market’s historical growth can be linked to the rising prevalence of peripheral artery disease, an increasing aging demographic, the high incidence of smoking-related vascular disorders, a growing cardiovascular disease burden, and the expanded availability of vascular intervention procedures.
The market size for intermittent claudication is anticipated to show considerable expansion over the next few years. It is projected to climb to $17.98 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.9%. This projected growth can be attributed to several factors, including increasing public knowledge of peripheral artery disease symptoms, a rising demand for less invasive vascular treatments, ongoing progress in pharmacological therapies, the growing acceptance of home-based disease management strategies, and enhancements in screening and diagnostic programs. Prominent trends expected during the forecast period encompass an intensified focus on the early diagnosis of peripheral artery disease, a rise in the use of combination drug therapies, a developing preference for minimally invasive revascularization procedures, the expansion of supervised exercise therapy programs, and improved patient awareness and overall disease management.
Get A Free Sample Report With In-Depth Market Insights:
Intermittent Claudication Market Growth Drivers: What’s Behind The Acceleration?
The escalating incidence of peripheral artery disease (PAD) is projected to boost the expansion of the intermittent claudication market moving ahead. PAD is a circulatory ailment characterized by constricted arteries that impede blood flow to the limbs, resulting in discomfort, numbness, and various complications. The rise in PAD diagnoses is linked to factors such as an aging demographic, diabetes, tobacco use, high blood pressure, excessive weight, and inactive lifestyles. PAD leads to intermittent claudication by diminishing the supply of blood to leg muscles during physical activity, which causes pain and cramping due to insufficient oxygen. For example, in June 2023, data from the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, indicated that peripheral artery disease (PAD) impacts 7-12 million individuals in the U.S. and 200 million people globally. Consequently, the growing prevalence of peripheral artery disease (PAD) is stimulating the development of the intermittent claudication market.
Intermittent Claudication Market Segment Performance And Emerging Opportunities
The intermittent claudication market covered in this report is segmented –
1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy
Intermittent Claudication Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies operating within the Intermittent Claudication market are focusing on integrating minimally invasive endovascular innovations, such as percutaneous bypass systems, to improve treatment efficiency, procedural success, and patient outcomes. Percutaneous bypass systems are sophisticated vascular technologies that establish an endovascular bypass pathway using specialized stent grafts and catheters, providing capabilities like restoring blood flow across long arterial blockages, reducing dependence on open surgical bypass, and supporting faster patient recovery. For instance, in June 2023, Endologix LLC, a US-based medical device company specializing in therapies for vascular disease, secured FDA approval for its DETOUR System, a minimally invasive percutaneous bypass solution designed to address long, complex superficial femoropopliteal lesions in patients with peripheral artery disease (PAD). This system incorporates the TORUS stent graft platform, a novel endovascular bypass technique, and the capacity to manage long-segment occlusions, enabling effective treatment of challenging femoropopliteal blockages. The DETOUR System significantly improves blood flow restoration, decreases procedural morbidity, and expands therapeutic options for patients with symptomatic PAD and intermittent claudication.
Intermittent Claudication Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma.
View The Full Intermittent Claudication Market Report:
Intermittent Claudication Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the intermittent claudication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








